Key result
Patients with at least one CYP2C9 variant allele had an increased risk of serious or life-threatening bleeding events during warfarin therapy compared with wild-type patients (HR 2.39; 95% CI 1.18-4.86).
Why the study?
Does the presence of CYP2C9*2 or CYP2C9*3 genetic variants increase the risk of overanticoagulation and bleeding events in patients receiving long-term warfarin therapy?
Population
200 patients receiving long-term warfarin therapy for various indications at 2 anticoagulation clinics in…
Comparison
Presence of at least 1 variant CYP2C9 allele vs Wild-type (*1/*1) CYP2C9 genotype
Design
Cohort
Authors
Loading...
May warrant closer INR monitoring in variant carriers; leaves open whether genotyping improves outcomes.
Cohort (n=200)
Yes
Does the presence of CYP2C9*2 or CYP2C9*3 genetic variants increase the risk of overanticoagulation and bleeding events in patients receiving long-term warfarin therapy?
Effect estimate: HR 2.39 (95% CI 1.18-4.86)
CYP2C9*2 and CYP2C9*3 genetic variants are associated with an increased risk of overanticoagulation and serious bleeding events during warfarin therapy, suggesting a potential role for genetic screening to guide dosing.
Mitchell K. Higashi (2002) conducted a cohort in Long-term warfarin therapy (n=200). CYP2C9*2 and CYP2C9*3 variant alleles vs. Wild-type (*1/*1) genotype was evaluated on Serious or life-threatening bleeding events (HR 2.39, 95% CI 1.18-4.86). Patients with at least one CYP2C9 variant allele had an increased risk of serious or life-threatening bleeding events during warfarin therapy compared with wild-type patients (HR 2.39; 95% CI 1.18-4.86).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: